Trial Profile
An Open-label, Dose-escalation, Bi-weekly Phase I+II Clinical Trial in Treating Patients With Locally Advanced and Metastatic Urothelial Carcinoma
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 29 Jun 2023
Price :
$35
*
At a glance
- Drugs Socazolimab (Primary)
- Indications Carcinoma; Urogenital cancer
- Focus Adverse reactions
- Sponsors Lee's Pharmaceutical
- 26 Sep 2018 New trial record